SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Recruiting at26 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Aldeyra Therapeutics, Inc.

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.

Research Team

Eligibility Criteria

Inclusion Criteria

Male or female subjects aged ≥ 18 years and ≤ 85 years.

Subjects with acute non-infectious anterior uveitis with onset of symptoms within the previous 2 weeks.

Best corrected visual acuity (BCVA) better than or equal to 35 letters in the study eye and 65 letters in the non-study eye using ETDRS testing.

Treatment Details

Interventions

• ADX-102 Ophthalmic Solution (0.5%) (Anti-inflammatory Agent)
• Vehicle of ADX-102 Ophthalmic Solution (Other)

Participant Groups

Group I: ADX-102 Ophthalmic Solution (0.5%) Experimental Treatment 1 Intervention

Group II: Vehicle of ADX-102 Ophthalmic Solution Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

Aldeyra Therapeutics, Inc.

Lead Sponsor

Trials

34

Recruited

4,700+